Stock listing
MLTX Stock Price, News, Filings & Events — Moonlake Immunotherapeutics
Selected listing: MLTX · NASDAQ · USD · US
This page tracks Moonlake Immunotherapeutics's MLTX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following MLTX:NASDAQ. MLTX:NASDAQ is the stock-level entry point for investors researching Moonlake Immunotherapeutics, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Moonlake Immunotherapeutics is a public company listed under the ticker MLTX, operating in the American market. The company has a market capitalization of approximately $1.63 billion. Moonlake focuses on developing innovative immunotherapies to address unmet medical needs.
- Ticker
- MLTX:NASDAQ
- Asset type
- Stock
- Market cap
- $1.06B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Moonlake Immunotherapeutics MLTX:NASDAQ stock context
This page tracks Moonlake Immunotherapeutics's MLTX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following MLTX:NASDAQ. MLTX:NASDAQ is the stock-level entry point for investors researching Moonlake Immunotherapeutics, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Moonlake Immunotherapeutics is a public company listed under the ticker MLTX, operating in the American market. The company has a market capitalization of approximately $1.63 billion. Moonlake focuses on developing innovative immunotherapies to address unmet medical needs.
Latest news from Moonlake Immunotherapeutics
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant...
August 10, 2026
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
June 23, 2026
MoonLake Immunotherapeutics Announces Proposed Public Offering
June 22, 2026
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on ...
June 21, 2026
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Fi...
May 10, 2026
Moonlake Immunotherapeutics earnings calls
Research Moonlake Immunotherapeutics
Moonlake Immunotherapeutics investor report
Review AI stock analysis and investor report context for MLTX:NASDAQ.
Moonlake Immunotherapeutics company profile
View the public company page for Moonlake Immunotherapeutics on 6ix.
Moonlake Immunotherapeutics news
Read company news and market updates connected to Moonlake Immunotherapeutics.
Moonlake Immunotherapeutics investor events
Find investor webinars, events, and replay context for Moonlake Immunotherapeutics.
Alternate listings
MLTX:BOATS
US · USD
Alternate listing for Moonlake Immunotherapeutics; the primary context on this page is MLTX:NASDAQ.
MLTXN:BIVA
MX · MXN
Alternate listing for Moonlake Immunotherapeutics; the primary context on this page is MLTX:NASDAQ.
MLTXN:BMV
MX · MXN
Alternate listing for Moonlake Immunotherapeutics; the primary context on this page is MLTX:NASDAQ.